FrancophonIA/ELRC3.0 huggingface dataset:
English: What is Glidipion?
Estonian: Mis on Glidipion?
English: What is the risk associated with Glidipion?
Estonian: Mis riskid Glidipioniga kaasnevad?
English: Glidipion can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: Glidipioni tohib kasutada ka koos insuliiniga patsientidel, kellele üksnes insuliini manustamine ei mõju piisavalt ja kes ei saa kasutada metformiini.
English: Why has Glidipion been approved?
Estonian: Miks Glidipion heaks kiideti?
English: Glidipion should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Estonian: Glidipioni ei tohi kasutada patsiendid, kes saavad dialüüsi (teatud verepuhastustehnika neeruhaiguste korral).
English: Therefore, the CHMP's view was that, as for Actos, the benefits outweigh the identified risks.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab ravimi Glidipioni kasulikkus sellega kaasnevad riskid.
English: EPAR summary for the public
Estonian: Kokkuvõte üldsusele pioglitasoon
English: Glidipion can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Estonian: Glidipioni tohib kasutada ka koos metformiiniga patsientidel, kelle haigus ainult metformiini kasutamisel rahuldavalt ravile ei allu, või koos sulfonüüluurearavimiga (samuti diabeediravim), kui metformiini ei saa kasutada (ravi kahe preparaadiga).
English: How has Glidipion been studied?
Estonian: Kuidas Glidipioni uuriti?
English: How is Glidipion used?
Estonian: Kuidas Glidipioni kasutatakse?
English: What is Glidipion used for?
Estonian: Milleks Glidipioni kasutatakse?
English: Glidipion can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy').
Estonian: Glidipioni tohib kasutada koos metformiini ja sulfonüüluurearavimiga patsientidel, kelle haigus ei allu piisavalt suukaudsele ravile kahe preparaadiga (ravi kolme preparaadiga).
English: How does Glidipion work?
Estonian: Kuidas Glidipion toimib?
English: Glidipion is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Estonian: Glidipioni kasutatakse ainsa ravimina patsientidel, kellele ei sobi metformiin (samuti diabeediravim).
English: - if you are pregnant.
Estonian: - kui olete rase.
English: Pregnancy.
Estonian: Rasedus.
English: Women who intend to become pregnant should be advised to delay.
Estonian: Naistele, kes kavatsevad rasestuda, tuleb soovitada see edasi lükata.
English: Whether you or your child receives the vaccine will depend upon the level of your immune defenses.
Estonian: Teie või teie lapse vaktsineerimine sõltub teie immuunkaitsevõime tasemest.
English: Warnings and precautions The text of this section should be read as follows:
Estonian: Hoiatused ja ettevaatusabinõud Selle lõigu tekst peab olema järgmine:
English: - if you or your child has any illness (such as Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)) or takes any medicine that weakens the immune system.
Estonian: - kui teil või teie lapsel on mõni haigus (nagu inimeste immuunpuudulikkuse viirus (HIV) või omandatud immuunpuudulikkuse sündroom (AIDS)) või kasutate mistahes ravimit, mis nõrgestab immuunsüsteemi.
English: Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infection or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25%; children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15% (see section 4.4).
Estonian: Tõsine humoraalne või rakutasandil (esmane või omandatud) immuunpuudulikkus, agammaglobulineemia ja AIDS või sümptomaatiline HIV-nakkus või vanusest sõltuv CD4+ Tlümfotsüütide protsendimäär lastel vanuses alla 12 kuu: CD4+ < 25%; lastel vanuses 12 kuni 35 kuud: CD4+ < 20%; lastel vanuses 36 kuni 59 kuud: CD4+ < 15% (vt lõik 4.4).
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before the vaccination is given.
Estonian: Kui olete rase, imetate või arvate end olevat rase või kavatsete rasestuda, pidage enne vaktsineerimist nõu oma arsti või apteekriga.
English: You or your child should be closely monitored as the responses to the vaccines may not be sufficient to ensure a protection against the illness (see section 2 “Do not use [PRODUCT NAME]”)
Estonian: Teid või teie last tuleb hoolikalt jälgida, kuna organismi vastus vaktsiinile ei pruugi olla piisav, et tagada kaitse haiguse vastu (vt lõik 2 “Ärge kasutage [RAVIMI NIMI]”)
English: Section 4.4 Special warnings and precautions for use The wording on pregnancy and breastfeeding should be deleted.
Estonian: Lõik 4.4 Erihoiatused ja ettevaatusabinõud kasutamisel Kustutada sõnastus raseduse ja imetamise kohta.
English: The wording regarding pregnancy should read as follows: “[PRODUCT NAME] should not be administrated to pregnant women.
Estonian: Raseduse kohta peab sõnastus olema järgmine: “Ärge manustage [RAVIMI NIMI] raseduse korral.
English: Even if a theoretical risk cannot be excluded yet, no cases of congenital rubella syndrome have been reported in more than 3500 susceptible women who were unknowingly in early stages of pregnancy when vaccinated with rubella containing vaccines.
Estonian: Olgugi et teoreetilist riski ei saa praeguseks veel välistada, ei ole teada ühtegi kaasasündinud punetistesündroomi juhtumit 3500 vastuvõtliku teadmata varases rasedusjärgus naise seast, keda oli sel hetkel vaktsineeritud punetisi sisaldavate vaktsiinidega.
English: The wording below should be inserted:
Estonian: Lisada järgnev sõnastus:
English: What you need to know before you use [PRODUCT NAME] Do not use [PRODUCT NAME]
Estonian: 2. Mida on vaja teada enne [RAVIMI NIMI] kasutamist Ärge kasutage [RAVIMI NIMI]
English: Section 4.6 Fertility, pregnancy and lactation The wording regarding pregnancy should read as follows:
Estonian: Lõik 4.6 Fertiilsus, rasedus ja imetamine Raseduse kohta peab sõnastus olema järgmine:
English: During this time you should use an effective method of birth control to avoid pregnancy.
Estonian: Kasutage selle aja jooksul mõjuvaid rasestumisvastaseid vahendeid.
English: The wording regarding pregnancy and immunocompromised patients should read as follows: The text of this section should be read as follows:
Estonian: Raseduse ning immuunpuudulikkusega patsientide kohta peab sõnastus olema järgmine: Selle lõigu tekst peab olema järgmine:
English: Talk to your doctor or pharmacist before you or your child receives [PRODUCT NAME]: - if you or your child has weakened immune system (e.g. such as HIV infection).
Estonian: Enne [RAVIMI NIMI] kasutamist endal või oma lapsel pidage nõu oma arsti või apteekriga: - kui teil või teie lapsel on nõrgenenud immuunsüsteem (nt HIV nakkus).
English: Vaccination may be considered in patients with selected immune deficiencies where the benefits outweigh the risks (e.g. asymptomatic HIV subjects, IgG subclass deficiencies, congenital neutropenia, chronic granulomatous disease, and complement deficiency diseases).
Estonian: Valikulise immuunpuudulikkusega patsiente võib vaktsineerida juhul, kui saadav kasu ületab riskid (nt asümptomaatilise HIV korral, IgG alamklassi puudulikkused, kaasasündinud neutropeenia, krooniline granulomatoosne haigus ning kaasnevad puudulikkushaigused).
English: The wording regarding pregnancy and immunocompromised patients should read as follows:
Estonian: Raseduse ning immuunpuudulikkusega patsientide kohta peab sõnastus olema järgmine:
English: Pregnancy should be avoided for 1 month following vaccination.
Estonian: Rasestumisest tuleb hoiduda 1 kuu jooksul pärast vaktsineerimist.
English: Section 4.3 Contraindications The wording regarding pregnancy and immunocompromised patients should read as follows:
Estonian: Lõik 4.3 Vastunäidustused Raseduse ning immuunpuudulikkusega patsientide kohta peab sõnastus olema järgmine:
English: In case of inadvertent vaccination of pregnant women with [PRODUCT NAME], this should not be a reason for termination of pregnancy.
Estonian: Raseda naise tahtmatu vaktsineerimine [RAVIMI NIMI]-ga ei ole põhjus raseduse katkestamiseks.
English: Furthermore, pregnancy should be avoided for 1 month following vaccination (see section
Estonian: Lisaks tuleb hoiduda rasestumisest 1 kuu jooksul pärast vaktsineerimist (vt lõik 4.6).
English: Annex III Amendments to relevant sections of the summaries of product characteristics and package leaflets
Estonian: III lisa Ravimi omaduste kokkuvõtte ja pakendi infolehe asjakohaste lõikude täiendused
English: These patients should be monitored carefully for signs of parotitis.
Estonian: Neid patsiente tuleb hoolikalt jälgida parotiidi sümptomite suhtes.
English: Also, it is important that you do not become pregnant within one month after having the vaccine.
Estonian: Lisaks on oluline, et hoidute rasestumisest ühe kuu jooksul pärast vaktsineerimist.
English: These patients should be monitored carefully for signs of measles, parotitis, rubella and varicella.
Estonian: Neid patsiente tuleb hoolikalt jälgida leetrite, parotiidi, punetiste ja tuulerõugete sümptomite suhtes.
English: These patients should be monitored carefully for signs of measles, parotitis and rubella.
Estonian: Neid patsiente tuleb hoolikalt jälgida leetrite, parotiidi ja punetiste sümptomite suhtes.
English: However, fetal damage has not been documented when mumps vaccines have been given to pregnant women.
Estonian: Siiski ei ole dokumenteeritud lootekahjustusi, kui raseduse korral on mumpsi vastu vaktsineeritud.
English: However, fetal damage has not been documented when measles, mumps or rubella vaccines have been given to pregnant women.
Estonian: Siiski ei ole dokumenteeritud lootekahjustusi, kui raseduse korral on leetrite, mumpsi või punetiste vastu vaktsineeritud.
English: In addition, pregnancy should be avoided for 1 month following vaccination.
Estonian: Lisaks hoiduge rasestumisest 1 kuu jooksul pärast vaktsineerimist.
English: However, fetal damage has not been documented when measles, mumps, rubella or varicella vaccines have been given to pregnant women.
Estonian: Siiski ei ole dokumenteeritud lootekahjustusi, kui raseduse korral on leetrite, mumpsi, punetiste või tuulerõugete vastu vaktsineeritud.
English: Amendments to be included in the relevant sections of the summary of product characteristics for multivalent measles, mumps, rubella and varicella containing vaccines
Estonian: Mitmevalentsete leetreid, mumpsi ja punetisi sisaldavate vaktsiinide ravimi omaduste kokkuvõtte asjakohaste lõikude täiendused
English: These patients should be monitored carefully for signs of measles and rubella.
Estonian: Neid patsiente tuleb hoolikalt jälgida leetrite ja punetiste sümptomite suhtes.
English: Therefore, inadvertent vaccination of unknowingly pregnant women with mumps containing vaccines should not be a reason for termination of pregnancy.
Estonian: Seepärast ei ole põhjust rasedust katkestada, kui teadmata raseduse korral on tahtmatult vaktsineeritud mumpsi sisaldava vaktsiiniga.
English: Amendments to be included in the relevant sections of the summary of product characteristics for monovalent mumps containing vaccines
Estonian: Ühevalentsete mumpsi sisaldavate vaktsiinide ravimi omaduste kokkuvõtte asjakohaste lõikude täiendused
English: Amendments to be included in the relevant sections of the package leaflet for monovalent mumps containing vaccines
Estonian: Ühevalentsete mumpsi sisaldavate vaktsiinide pakendi infolehe asjakohaste lõikude täiendused
English: These patients should be monitored carefully for signs of measles.
Estonian: Neid patsiente tuleb hoolikalt jälgida leetrite sümptomite suhtes.
English: Therefore, inadvertent vaccination of unknowingly pregnant women with measles, mumps and rubella containing vaccines should not be a reason for termination of pregnancy.
Estonian: Seepärast ei ole põhjust rasedust katkestada, kui teadmata raseduse korral on tahtmatult vaktsineeritud leetreid, mumpsi ja punetisi sisaldava vaktsiiniga.
English: These patients should be monitored carefully for signs of rubella.
Estonian: Neid patsiente tuleb hoolikalt jälgida punetiste sümptomite suhtes.
English: Amendments to be included in the relevant sections of the summary of product characteristics for multivalent measles and rubella containing vaccines
Estonian: Mitmevalentsete leetreid ja punetisi sisaldavate vaktsiinide ravimi omaduste kokkuvõtte asjakohaste lõikude täiendused
English: Therefore, inadvertent vaccination of unknowingly pregnant women with measles containing vaccines should not be a reason for termination of pregnancy.
Estonian: Seepärast ei ole põhjust rasedust katkestada, kui teadmata raseduse korral on tahtmatult vaktsineeritud leetreid sisaldava vaktsiiniga.
English: However, fetal damage has not been documented when measles or rubella vaccines have been given to pregnant women.
Estonian: Siiski ei ole dokumenteeritud lootekahjustusi, kui raseduse korral on leetrite või punetiste vastu vaktsineeritud.
English: Amendments to be included in the relevant sections of the package leaflet for multivalent measles and rubella containing vaccines
Estonian: Mitmevalentsete leetreid ja punetisi sisaldavate vaktsiinide pakendi infolehe asjakohaste lõikude täiendused
English: Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects, therefore some of these patients may acquire measles, mumps, rubella or varicella in case of contact, despite appropriate vaccine administration.
Estonian: Immuunpuudulikkusega patsiendid, kellel puuduvad selle vaktsineerimise suhtes vastunäidustused (vt lõik 4.3), ei pruugi reageerida sama hästi kui immuunsusega isikud, mistõttu mõned neist patsientidest võivad kontakti korral siiski leetritesse, mumpsi, punetistesse või tuulerõugetesse nakatuda.
English: Amendments to be included in the relevant sections of the package leaflet for monovalent rubella containing vaccines
Estonian: Ühevalentsete punetisi sisaldavate vaktsiinide pakendi infolehe asjakohaste lõikude täiendused
English: Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects, therefore some of these patients may acquire mumps in case of contact, despite appropriate vaccine administration.
Estonian: Immuunpuudulikkusega patsiendid, kellel puuduvad selle vaktsineerimise suhtes vastunäidustused (vt lõik 4.3), ei pruugi reageerida sama hästi kui immuunsusega isikud, mistõttu mõned neist patsientidest võivad kontakti korral siiski mumpsi nakatuda.
English: However, fetal damage has not been documented when measles vaccines have been given to pregnant women.
Estonian: Siiski ei ole dokumenteeritud lootekahjustusi, kui raseduse korral on leetrite vastu vaktsineeritud.
English: However, fetal damage has not been documented when rubella vaccines have been given to pregnant women.
Estonian: Siiski ei ole dokumenteeritud lootekahjustusi, kui raseduse korral on punetiste vastu vaktsineeritud.
English: Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects, therefore some of these patients may acquire measles, mumps or rubella in case of contact, despite appropriate vaccine administration.
Estonian: Immuunpuudulikkusega patsiendid, kellel puuduvad selle vaktsineerimise suhtes vastunäidustused (vt lõik 4.3), ei pruugi reageerida sama hästi kui immuunsusega isikud, mistõttu mõned neist patsientidest võivad kontakti korral siiski leetritesse, mumpsi või punetistesse nakatuda.
English: Amendments to be included in the relevant sections of the summary of product characteristics for monovalent rubella containing vaccines
Estonian: Ühevalentsete punetisi sisaldavate vaktsiinide ravimi omaduste kokkuvõtte asjakohaste lõikude täiendused
English: Amendments to be included in the relevant sections of the package leaflet for multivalent measles, mumps and rubella containing vaccines 2.
Estonian: Mitmevalentsete leetreid, mumpsi ja punetisi sisaldavate vaktsiinide pakendi infolehe asjakohaste lõikude täiendused
English: Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects, therefore some of these patients may acquire measles in case of contact, despite appropriate vaccine administration.
Estonian: Immuunpuudulikkusega patsiendid, kellel puuduvad selle vaktsineerimise suhtes vastunäidustused (vt lõik 4.3), ei pruugi reageerida sama hästi kui immuunsusega isikud, mistõttu mõned neist patsientidest võivad kontakti korral siiski leetritesse nakatuda.
English: Amendments to be included in the relevant sections of the package leaflet for monovalent measles containing vaccines
Estonian: Ühevalentsete tuulerõugeid sisaldavate vaktsiinide pakendi infolehe asjakohaste lõikude täiendused
English: Amendments to be included in the relevant sections of the summary of product characteristics for monovalent measles containing vaccines
Estonian: Ühevalentsete leetreid sisaldavate vaktsiinide ravimi omaduste kokkuvõtte asjakohaste lõikude täiendused
English: Therefore, inadvertent vaccination of unknowingly pregnant women with measles and rubella containing vaccines should not be a reason for termination of pregnancy.
Estonian: Seepärast ei ole põhjust rasedust katkestada, kui teadmata raseduse korral on tahtmatult vaktsineeritud leetreid ja punetisi sisaldava vaktsiiniga.
English: Therefore, inadvertent vaccination of unknowingly pregnant women with rubella containing vaccines should not be a reason for termination of pregnancy.
Estonian: Seepärast ei ole põhjust rasedust katkestada, kui teadmata raseduse korral on tahtmatult vaktsineeritud punetisi sisaldava vaktsiiniga.
English: Betaferon received a marketing authorisation valid throughout the EU on 30 November 1995.
Estonian: Betaferon on saanud müügiloa, mis kehtib kogu ELis, 30. novembril 1995.
English: What measures are being taken to ensure the safe and effective use of Betaferon?
Estonian: Mis meetmed võetakse, et tagada Betaferoni ohutu ja efektiivne kasutamine?
English: Further information on Betaferon can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/betaferon.
Estonian: Lisateave Betaferoni kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/betaferon.
English: Other information about Betaferon
Estonian: Muu teave Betaferoni kohta
English: What is Betaferon and what is it used for?
Estonian: Mis on Betaferon ja milleks seda kasutatakse?
English: The European Medicines Agency decided that Betaferon's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Betaferoni kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Side effects are common at the beginning of treatment but usually decrease with further treatment.
Estonian: Kõrvalnähud on ravi alguses sagedad, kuid vähenevad tavaliselt edasise ravi käigus.
English: Why is Betaferon authorised in the EU?
Estonian: Miks Betaferon ELis heaks kiideti?
English: As for all medicines, data on the use of Betaferon are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Betaferoni kasutamise kohta pidevat järelevalvet.
English: Side effects reported with Betaferon are carefully evaluated and any necessary action taken to protect patients.
Estonian: Betaferoni kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Betaferon (interferon beta-1b)
Estonian: Betaferon (beeta-1b-interferoon)
English: Betaferon is used in patients:
Estonian: Betaferoni kasutatakse järgmistel patsientidel:
English: Treatment should start with 62.5 micrograms (a quarter of the dose) every other day, increasing progressively over 19 days to reach the recommended dose of 250 micrograms given every other day.
Estonian: Ravi alguses manustatakse ülepäeviti 62,5 µg (neljandik annust) ja seejärel suurendatakse annust järk-järgult 19 päeva jooksul, et saavutada soovitatav annus 250 µg, mis manustatakse ülepäeviti.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Betaferon have been included in the summary of product characteristics and the package leaflet.
Estonian: Betaferoni ohutu ja efektiivse kasutamise soovitused ning ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Betaferon, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Betaferoni kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: • who have experienced the signs of MS for the first time, and these are severe enough to need treatment with injected corticosteroids (anti-inflammatory medicines).
Estonian: • patsiendid, kellel tekkisid hulgiskleroosi sümptomid esimest korda ja need on piisavalt rasked, et vajada ravi süstitavate kortikosteroididega (põletikuvastased ravimid).
English: What are the risks associated with Betaferon?
Estonian: Mis riskid Betaferoniga kaasnevad?
English: In the other study, no delay in the time to disability progression was seen.
Estonian: Teises uuringus ei täheldatud puude süvenemiseni kulunud aja pikenemist.
English: Betaferon must not be used in patients who have decompensated liver disease (when the liver is damaged and can no longer work adequately).
Estonian: Betaferoni ei tohi kasutada patsiendid, kellel on dekompenseeritud maksahaigus (olukord, kus maks on kahjustunud ega toimi enam normaalselt).
English: The most frequent side effects with Betaferon are flu-like symptoms (including fever, chills, joint pain, malaise [feeling unwell], sweating, headache and muscle pain) and reactions at the site of injection.
Estonian: Betaferoni kõige sagedamad kõrvalnähud on gripilaadsed sümptomid (sh palavik, külmavärinad, liigesevalu, halb enesetunne, higistamine ja lihasevalu) ning süstekoha reaktsioonid.
English: The exact way that Betaferon works in MS is not yet known but the active substance, interferon beta-1b, seems to calm down the immune system, and prevents relapses of MS.
Estonian: Betaferoni täpne toimemehhanism hulgiskleroosi korral ei ole veel teada, kuid selle toimeaine beeta-1b-interferoon näib vähendavat immuunsüsteemi aktiivsust, hoides ära hulgiskleroosi relapside teket.
English: Betaferon was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27.
Estonian: Betaferon oli aastase relapside arvu vähendamisel efektiivsem kui platseebo: ravimit saanud patsientidel tekkis aastas keskmiselt 0,84 relapsi ja platseebot saanud patsientidel 1,27 relapsi.
English: One of the two studies showed a significant delay in the time to disability progression (31% risk reduction due to Betaferon) and in the time to becoming wheelchair bound (39%).
Estonian: Üks uuringutest tõendas, et aeg puude süvenemiseni (Betaferoni tõttu vähenes risk 31%) ja ratastooli jäämiseni (39%) pikenes oluliselt.
English: Betaferon must not be used in patients who have severe depression or have thoughts of suicide.
Estonian: Betaferoni ei tohi kasutada raske depressiooni või suitsiidimõtetega patsiendid.
English: • who have MS of the type known as ‘relapsing-remitting', when the patient has attacks (relapses) between periods with no symptoms (remissions), in patients with at least two relapses within the last two years;
Estonian: • patsiendid, kellel on hulgiskleroosi relapseeruv-remiteeruv vorm, kui patsiendil esinevatele relapsidele ehk haiguse ägenemistele järgnevad remissioonid ehk sümptomiteta perioodid ning kui kahel viimasel aastal esines vähemalt kaks relapsi;